Karl Dane Wittrup

Karl Dane Wittrup has held a variety of positions in academia and the biotechnology industry since 1999. Karl Dane began their career as C.P. Dubbs Professor at the Massachusetts Institute of Technology (MIT) in 1999, and later took on the role of Associate Director of the Koch Institute in 2007. In 2015, they joined the Scientific Advisory Board of Mersana Therapeutics, and in 2017 they joined the Scientific Advisory Board of Dragonfly Therapeutics, Inc. In 2018, they joined the Scientific Advisory Board of Werewolf Therapeutics and in 2019 they joined the Scientific Advisory Board of Strand Therapeutics. In 2019, they co-founded Immunitas Therapeutics and in 2020 they co-founded Ankyra Therapeutics and Cullinan Amber LLC. In 2021, they co-founded 76Bio, Inc. and joined its Scientific Advisory Board.

Karl Dane Wittrup obtained their B.S. in Chemical Engineering from The University of New Mexico in 1984, followed by a Ph.D. in Chemical Engineering from Caltech in 1988.